TNFSF10 and prostate neoplasm: Hesry et al. [41] showed that sensitivity to the TRAIL ligand is related to tumour progression (in LNCaP, DU 145, PC3 cells) and that TRAIL-induced cell death is only linked to the DR5 receptor, moreover they found DcR1 receptor expression to be undetectable, whereas DcR2 was significantly more abundant in tumour cells than non-neoplastic cells, and may thus contribute to the partial resistance to TRAIL found in some prostate tumour cells (e.g. LNCaP and DU 145).